Navigation Links
New Company to Develop Nutritional Interventions Against Chronic Inflammatory and Infectious Diseases
Date:10/17/2008

BLACKSBURG, Va., Oct. 17 /PRNewswire-USNewswire/ -- A new company is being created as a spin-off from Virginia Tech research to develop nutritional interventions against chronic inflammatory and infectious diseases. BioTherapeutics Inc. will promote health and well-being through the discovery and development of nutraceuticals -- naturally occurring molecules that can be integrated into nutritional products and functional food ingredients.

BioTherapeutics Inc. was newly incorporated in August, 2008, with the purpose of introducing novel Virginia Tech-developed nutraceutical technologies into the marketplace. The company was founded by Dr. Josep Bassaganya-Riera, Associate Professor at the Virginia Bioinformatics Institute at Virginia Tech, who has more than 15 years experience working at the interface between immunology and nutrition. Dr. Bassaganya-Riera said, "BioTherapeutics Inc. will provide a platform for translating new scientific knowledge arising from leading university research into products and technologies that improve people's health and well-being."

The mission of BioTherapeutics Inc. is to develop novel, orally active, naturally occurring compounds that have proven scientific efficacy and have been shown by clinical research to have substantial health claims. Each technology in BioTherapeutics' product pipeline has shown efficacy in mouse studies and is linked to chronic inflammatory or infectious disease prevention or treatment. BioTherapeutics has already licensed three U.S. patents from VTIP and filed another in Europe.

The products developed by the company will be based on technologies licensed to BioTherapeutics Inc. by Virginia Tech Intellectual Properties (VTIP). VTIP works with inventors to identify companies that may be interested in Virginia Tech inventions, negotiates licensing agreements and manages the income from royalties and licensing fees that is shared with inventors and Virginia Tech. The technologies were developed from Dr. Josep Bassaganya-Riera's work at VBI and Virginia Tech's Department of Human Nutrition, Foods and Exercise.

"We are always pleased to license university-owned technologies to start-up companies formed by faculty entrepreneurs," said Mark Coburn, president of VTIP. "This is an important component of VTIP's mission. We like to encourage and cultivate the entrepreneurial spirit of faculty inventors and assist companies like BioTherapeutics in the further development of their licensed intellectual property portfolio. Through these activities we hope to support economic development in southwest Virginia."

Learn more about Dr. Bassaganya-Riera, his research, and his publications at http://www.vbi.vt.edu/faculty/personal_pages/josep_bassaganya-riera.

About BioTherapeutics Inc.

BioTherapeutics Inc. was created to develop a diversified pipeline of novel nutritionals with strong intellectual property protection. Its core business is the development of "nutraceuticals," which are naturally occurring ingredients for nutritional supplement and functional foods. BioTherapeutics Inc. focuses on developing nutritional, preventative and therapeutic interventions against chronic inflammatory and infectious diseases. BioTherapeutics Inc. plans to partner with other nutritional supplement manufacturers and pharmaceutical companies in the joint development of ground-breaking, evidence-based nutritional technologies by implementing product-specific research & development plans and commercialization agreements.

About the Virginia Bioinformatics Institute

The Virginia Bioinformatics Institute (VBI) at Virginia Tech has a research platform centered on understanding the "disease triangle" of host-pathogen-environment interactions in plants, humans and other animals. By successfully channeling innovation into transdisciplinary approaches that combine information technology and biology, researchers at VBI are addressing some of today's key challenges in the life sciences. http://www.vbi.vt.edu

About Virginia Tech Intellectual Properties, Inc. (VTIP)

Formed in 1985 as an affiliated corporation of Virginia Tech, VTIP is passionate in its pursuit of excellence in technology commercialization, creating market opportunities from scientific innovation. We strive to make a positive contribution to society through our expertise in protecting, marketing and commercializing technology and innovation. Our goal is to pursue innovative strategies to help translate scientific progress into tangible products, while returning income to the inventor and Virginia Tech to support further research and education. VTIP facilitates the licensing of technology to companies, encourages new faculty startup ventures, works with publishers and distributors of software, and supports the transfer of research and knowledge to other universities, research institutes and companies. For more information about VTIP, visit http://www.vtip.org.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.


'/>"/>
SOURCE Virginia Tech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
4. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
5. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
6. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
7. NASA technology forms the basis for a new nanotechnology company
8. Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner
9. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
10. Monsanto Company Signs Share Subscription Agreement With Devgen
11. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 2016 Regen BioPharma, ... RGBPP) announced today initiation of a preclinical development ... based cancer immunotherapeutic product leveraging its NR2F6 immunological ... a generation of cord blood derived killer cells ...  The product in development will be a "universal ...
(Date:5/18/2016)... ... May 18, 2016 , ... Shimadzu Scientific Instruments ... University of Toledo. This two-day camp will take place annually starting June 2016. ... of pharmaceutical sciences in preparation for a university academic program. , The ...
(Date:5/18/2016)... (PRWEB) , ... May 18, 2016 , ... ... 1,200 hospitalizations are a direct result of asthma complications.* Costing more than $56 ... the country. , “For too many, the suffering associated with ...
(Date:5/17/2016)... 2016 Haselmeier announces the launch ... approval by EMA, the European Medicines Agency. Originally launched ... company, the new pen version includes enhancements to further ... confidence to patients during use. Its enhanced ... to handle with a larger display window that improves ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):